PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-68.91%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-77.36%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-159.79%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-169.49%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-182.97%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-183.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-183.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-87.94%
Negative 10Y revenue/share CAGR while 4997.T stands at 36.49%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
4.60%
5Y revenue/share CAGR under 50% of 4997.T's 36.49%. Michael Burry would suspect a significant competitive gap or product weakness.
-8.34%
Negative 3Y CAGR while 4997.T stands at 9.08%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
100.00%
10Y OCF/share CAGR in line with 4997.T's 100.00%. Walter Schloss would see both as similarly efficient over the decade.
100.00%
5Y OCF/share CAGR is similar to 4997.T's 100.00%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
No Data
No Data available this quarter, please select a different quarter.
87.54%
Net income/share CAGR at 50-75% of 4997.T's 126.36%. Martin Whitman might question if the firm’s product or cost base lags behind.
23.05%
Below 50% of 4997.T's 126.36%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-73.68%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
194.11%
Equity/share CAGR of 194.11% while 4997.T is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
137.30%
3Y equity/share CAGR above 1.5x 4997.T's 35.92%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.77%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
43.91%
Inventory growth well above 4997.T's 4.98%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
5.44%
Positive asset growth while 4997.T is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-2.72%
We have a declining book value while 4997.T shows 0.72%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
22.61%
Debt growth far above 4997.T's 0.78%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-100.00%
Our R&D shrinks while 4997.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-11.91%
We cut SG&A while 4997.T invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.